DocCode - SEQ.TXT
`
`SCORE Placeholder Sheet for IFW Content
`
`Application Number: 154 71506
`
`Document Date: 03/28/2017
`
`The presence of this form in the IFW record indicates that the following document type was received
`in electronic format on the date identified above. This content is stored in the SCORE database.
`
`Since this was an electronic submission, there is no physical artifact folder, no artifact folder is
`recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW
`record were created from the original documents that are stored in SCORE .
`
`• Sequence Listing
`
`At the time of document entry (noted above):
`• USPTO employees may access SCORE content via eDAN using the Supplemental Content
`tab, or via the SCORE web page.
`• External customers may access SCORE content via PAIR using the Supplemental Content
`tab.
`
`Form Revision Date: August 26, 2013
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 001
`
`

`

`PRELIMINARY
`AMENDMENT
`Under CFR 1.115
`
`Address to:
`Mail Stop Patent Application
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Sir:
`
`Electronically Filed
`REGN-008CIPCON2
`Attorney Docket No.
`To Be Assigned
`Confirmation No.
`Y ANCOPOULOS, GEORGE D.
`First Named Inventor
`To Be Assigned
`Application Number
`March 28, 2017
`Filing Date
`To Be Assigned
`Group Art Unit
`To Be Assigned
`Examiner Name
`Title:
`"Use of a VEGF Antagonist to Treat Angiogenic
`Eye Disorders"
`
`Prior to the examination of the above-referenced application on the merits, please enter the
`amendments below.
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 002
`
`

`

`Atty Dkt. No.: REGN-008CIPCON2
`USSN: To Be Assigned
`
`AMENDMENTS TO THE SPECIFICATION
`
`Please amend paragraph [0001] on pagel of the specification to read as follows:
`
`[0001] This application is a continuation of U.S. Patent Application Serial No. 14/972,560, filed
`
`December 17, 2015 (now allowed) which is a continuation of U.S. Patent Application Serial No.
`
`13/940,370 filed July 12, 2013, now U.S. Patent No. 9,254,338 issued February 9, 2016 which is a
`
`continuation-in-part of International Patent Application No. PCT/US2012/020855, filed on January 11,
`
`2012, which claims the benefit of US Provisional Application Nos. 61/432,245, filed on January 13,
`
`2011, 61/434,836, filed on January 21, 2011, and 61/561,957, filed on November 21, 2011, the contents
`
`of which are hereby incorporated by reference in their entireties.
`
`2
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 003
`
`

`

`Atty Dkt. No.: REGN-008CIPCON2
`USSN: To Be Assigned
`
`AMENDMENTS TO THE CLAIMS
`
`1. - 20. (Canceled)
`
`21.
`
`(New) A method for treating an angiogenic eye disorder in a patient, said method
`
`comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed
`
`by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the
`
`VEGF antagonist;
`
`wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose;
`
`and
`
`wherein each tertiary dose is administered at least 8 weeks after the immediately preceding dose;
`
`wherein the VEGF antagonist is a VEGF receptor-based chimeric molecule comprising (1) a
`
`VEGFRl component comprising amino acids 27 to 129 of SEQ ID N0:2; (2) a VEGFR2 component
`
`comprising amino acids 130-231 of SEQ ID N0:2; and (3) a multimerization component comprising
`
`amino acids 232-457 of SEQ ID N0:2;
`
`wherein exclusion criteria for the patient include all of:
`
`(1) active intraocular inflammation;
`
`(2) active ocular or periocular infection;
`
`(3) any ocular or periocular infection within the last 2 weeks prior to treatment.
`
`22.
`
`(New) The method of claim 21, wherein only a single secondary dose is administered to
`
`the patient, and wherein the single secondary dose is administered 4 weeks after the initial dose of the
`
`VEGF antagonist.
`
`23.
`
`(New) The method of claim 21, wherein only two secondary doses are administered to the
`
`patient, and wherein each secondary dose is administered 4 weeks after the immediately preceding dose.
`
`24.
`
`(New) The method of claim 23, wherein each tertiary dose is administered 8 weeks after
`
`the immediately preceding dose.
`
`25.
`
`(New) The method of claim 21, wherein at least 5 tertiary doses of the VEGF antagonist
`
`are administered to the patient, and wherein the first four tertiary doses are administered 8 weeks after
`
`3
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 004
`
`

`

`Atty Dkt. No.: REGN-008CIPCON2
`USSN: To Be Assigned
`
`the immediately preceding dose, and wherein each subsequent tertiary dose is administered 8 or 12
`
`weeks after the immediately preceding dose.
`
`26.
`
`(New) The method of claim 21, wherein the angiogenic eye disorder is selected from the
`
`group consisting of: age related macular degeneration, diabetic retinopathy, diabetic macular edema,
`
`central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
`
`27.
`
`(New) The method of claim 26, wherein the angiogenic eye disorder is age related
`
`macular degeneration.
`
`28.
`
`(New) The method of claim 21, wherein all doses of the VEGF antagonist are
`
`administered to the patient by topical administration or by intraocular administration.
`
`29.
`
`(New) The method of claim 28, wherein all doses of the VEGF antagonist are
`
`administered to the patient by intraocular administration.
`
`30.
`
`(New) The method of claim 29, wherein the intraocular administration is intravitreal
`
`administration.
`
`31.
`
`(New) The method of claim 30, wherein all doses of the VEGF antagonist comprise from
`
`about 0.5 mg to about 2 mg of the VEGF antagonist.
`
`32.
`
`(New) The method of claim 31, wherein all doses of the VEGF antagonist comprise 0.5
`
`mg of the VEGF antagonist.
`
`33.
`
`(New) The method of claim 31, wherein all doses of the VEGF antagonist comprise 2 mg
`
`of the VEGF antagonist.
`
`34.
`
`(New) A method for treating an angiogenic eye disorder in a patient, said method
`
`comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed
`
`by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the
`
`VEGF antagonist;
`
`wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose;
`
`and
`
`wherein each tertiary dose is administered at least 8 weeks after the immediately preceding dose;
`4
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 005
`
`

`

`Atty Dkt. No.: REGN-008CIPCON2
`USSN: To Be Assigned
`
`wherein the VEGF antagonist is a VEGF receptor-based chimeric molecule comprising
`
`VEGFR1R2-Fci1Cl(a) encoded by the nucleic acid sequence of SEQ ID N0:1;
`
`wherein exclusion criteria for the patient include all of:
`
`(1) active intraocular inflammation;
`
`(2) active ocular or periocular infection;
`
`(3) any ocular or periocular infection within the last 2 weeks prior to treatment.
`
`35.
`
`(New) The method of claim 34, wherein only a single secondary dose is administered to
`
`the patient, and wherein the single secondary dose is administered 4 weeks after the initial dose of the
`
`VEGF antagonist.
`
`36.
`
`(New) The method of claim 34, wherein only two secondary doses are administered to the
`
`patient, and wherein each secondary dose is administered 4 weeks after the immediately preceding dose.
`
`37.
`
`(New) The method of claim 36, wherein each tertiary dose is administered 8 weeks after
`
`the immediately preceding dose.
`
`38.
`
`(New) The method of claim 37, wherein the angiogenic eye disorder is age related
`
`macular degeneration.
`
`39.
`
`(New) The method of claim 34, wherein at least 5 tertiary doses of the VEGF antagonist
`
`are administered to the patient, and wherein the first four tertiary doses are administered 8 weeks after
`
`the immediately preceding dose, and wherein each subsequent tertiary dose is administered 8 or 12
`
`weeks after the immediately preceding dose.
`
`40.
`
`(New) The method of claim 34, wherein the angiogenic eye disorder is selected from the
`
`group consisting of: age related macular degeneration, diabetic retinopathy, diabetic macular edema,
`
`central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
`
`41.
`
`(New) The method of claim 34, wherein all doses of the VEGF antagonist are
`
`administered to the patient by topical administration or by intraocular administration.
`
`42.
`
`(New) The method of claim 41, wherein all doses of the VEGF antagonist are
`
`administered to the patient by intraocular administration.
`
`5
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 006
`
`

`

`Atty Dkt. No.: REGN-008CIPCON2
`USSN: To Be Assigned
`
`43.
`
`(New) The method of claim 41, wherein the intraocular administration is intravitreal
`
`administration.
`
`44.
`
`(New) The method of claim 43, wherein all doses of the VEGF antagonist comprise from
`
`about 0.5 mg to about 2 mg of the VEGF antagonist.
`
`45.
`
`(New) The method of claim 44, wherein all doses of the VEGF antagonist comprise 0.5
`
`mg of the VEGF antagonist.
`
`46.
`
`(New) The method of claim 44, wherein all doses of the VEGF antagonist comprise 2
`
`mg of the VEGF antagonist.
`
`6
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 007
`
`

`

`Atty Dkt. No.: REGN-008CIPCON2
`USSN: To Be Assigned
`
`REMARKS UNDER 37 CFR § 1.115
`
`Formal Matters
`
`Claims 21-46 are pending after entry of the amendments set forth herein.
`
`Claims 1-20 are canceled without prejudice.
`
`Claims 21-46 are added.
`
`Claims 21-46 are identical to claims 1-26 of issued U.S. Patent 9,254,338 with two exceptions.
`
`Specifically, the independent claims 21 and 34 include limitations with respect to exclusion criteria for
`
`patients. These exclusion criteria are disclosed within the original application in paragraph [0050].
`
`Specifically, they are the exclusion criteria 18, 19 and 20 of paragraph [0050].
`
`The specification has been amended to update the cross-reference to related application section.
`
`No new matter has been added.
`
`PARENT APPLICATION
`
`The parent application has been allowed. Further, as indicated above, correspondence and
`
`support for the current claims relative to those of the parent application can be reviewed and confirmed.
`
`In the event the Examiner has any questions with respect to claim support or other issues in connection
`
`with the application, the Examiner is respectfully requested to contact the undersigned attorney at the
`
`indicated telephone number to arrange for an interview to expedite this position of this application.
`
`STATEMENT UNDER 37 C.F.R. §§1.56 AND 1.2
`
`Applicants hereby advise the Examiner of the status of a co-pending application in compliance
`
`with the Applicant's duty to disclose under 37 C.F.R. §§1.56 and 1.2 ( see also MPEP §2001.06(b)) as
`
`discussed in McKesson Info. Soln. Inc., v. Bridge Medical Inc., 487 F.3d 897; 82 USPQ2d 1865 (Fed.
`
`Cir. 2007).
`
`The Applicants wish to bring to the Examiner's attention U.S. Patent Application No.
`
`13/940,370, filed July 12, 2013 which issued on February 9, 2016 as U.S. Patent 9,254,338.
`
`The Applicants wish to bring to the Examiner's attention that a Notice of Allowance was mailed
`
`on March 6, 2017 and the issue fee was paid on March 28, 2017 in co-pending U.S. Patent Application
`
`No. 14/972,560, filed December 17, 2015.
`
`7
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 008
`
`

`

`Atty Dkt. No.: REGN-008CIPCON2
`USSN: To Be Assigned
`
`These documents are available on PAIR, and thus are not provided with this
`
`communication. Please inform the undersigned if there is any difficulty in obtaining the documents
`
`from PAIR.
`
`CONCLUSION
`
`Applicant submits that all of the claims are in condition for allowance, which action is requested.
`
`If the Examiner finds that a telephone conference would expedite the prosecution of this application,
`
`please telephone the undersigned at the number provided.
`
`The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of
`
`$3,000.00 beyond that authorized on the credit card, but not more than $3,000.00 in additional fees due
`
`with any communication for the above referenced patent application, including but not limited to any
`
`necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No.
`
`50-0815, order number REGN-008CIPCON2.
`
`Respectfully submitted,
`BOZICEVIC, FIELD & FRANCIS LLP
`
`By: __ /_K_ar_l_B_o_z_ic_e_v_ic~,_R_e __ g __ ._N_o_._2_8~,8_0_7_/_
`Karl Bozicevic
`Registration No. 28,807
`
`Date:
`
`28 March 2017
`- - - - - - - - - - - -
`
`Bozicevic, Field & Francis LLP
`201 Redwood Shores Parkway, Suite 200
`Redwood City, California 94065
`Telephone: (650) 327-3400
`Direct: (650) 833-7735
`Facsimile: (650) 327-3231
`
`8
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 009
`
`

`

`Electronically Filed
`
`NOTIFICATION OF PRIOR
`SEQUENCE LISTING
`
`Attorney Docket
`
`REGN-008CIPCON2
`
`First Named Inventor
`
`Y ANCOPOULOS,
`GEORGED.
`
`Address to:
`Mail Stop Patent Application
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Sir:
`
`Application Number
`
`To Be Assigned
`
`Filing Date
`
`28 March 2017
`
`Confirmation Number
`
`To Be Assigned
`
`Group Art Unit
`
`To Be Assigned
`
`Examiner Name
`
`To Be Assigned
`
`Title:
`
`"USE OF A VEGF ANTAGONIST TO TREAT
`ANGIOGENIC EYE DISORDERS"
`
`The above-identified patent application contains sequences of nucleic acid and
`
`polypeptides. A sequence listing was prepared for parent application, 14/927,560, filed
`
`December 17, 2015, in paper and computer-readable format. The sequence information in the
`
`paper or compact disk copy of the sequence listing (required by 1.82l(c)) of this application is
`
`identical to the sequence information in the computer-readable format (CRF) of the above(cid:173)
`
`identified other application. No new matter has been added. Therefore, please transfer to this
`
`application, in accordance with 37 CFR § 1.82l(e), the fully compliant computer readable copy
`
`from applicants' other application. A paper (.txt) copy of this sequence listing is enclosed.
`
`Applicants respectfully submit that the present patent application is now in compliance
`
`with 37 CFR §§ 1.821 - 1.825. The Commissioner is hereby authorized to charge any
`
`underpayment of fees associated with this communication, including any necessary fees for
`
`extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number
`
`REGN-008CIPCON2.
`
`Respectfully submitted,
`
`BOZICEVIC, FIELD & FRANCIS LLP
`
`/Karl Bozicevic, Reg. No. 28,807/
`Karl Bozicevic
`Registration No. 28,807
`
`Dated:
`
`28 March 2017
`
`By:
`
`BOZICEVIC, FIELD & FRANCIS LLP
`201 Redwood Shores Parkway, Suite 201
`Redwood City, California 94065
`Telephone: (650) 327-3400
`Facsimile: (650) 327-3231
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 010
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`Title of Invention:
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`First Named Inventor/Applicant Name:
`
`GEORGE D. YANCOPOULOS
`
`Filer:
`
`Karl Bozicevic/Kimberly Zuehlke
`
`Attorney Docket Number:
`
`REGN-008CIPCON2
`
`Filed as Large Entity
`
`Filing Fees for Utility under 35 USC 111 (a)
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`UTILITY APPLICATION FILING
`
`UTILITY SEARCH FEE
`
`UTILITY EXAMINATION FEE
`
`1011
`
`1111
`
`1311
`
`1
`
`1
`
`1
`
`280
`
`600
`
`720
`
`280
`
`600
`
`720
`
`Basic Filing:
`
`Pages:
`
`Claims:
`
`CLAIMS IN EXCESS OF 20
`
`1202
`
`6
`
`80
`
`480
`
`Miscellaneous-Filing:
`
`Petition:
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 011
`
`

`

`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`Extension-of-Time:
`
`Miscellaneous:
`
`Total in USO($)
`
`2080
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 012
`
`

`

`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`28758182
`
`15471506
`
`International Application Number:
`
`Confirmation Number:
`
`8014
`
`Title of Invention:
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`First Named Inventor/Applicant Name:
`
`GEORGE D. YANCOPOULOS
`
`Customer Number:
`
`96387
`
`Filer:
`
`Karl Bozicevic
`
`Filer Authorized By:
`
`Attorney Docket Number:
`
`REGN-008CIPCON2
`
`Receipt Date:
`
`28-MAR-2017
`
`Filing Date:
`
`Time Stamp:
`
`15:02:24
`
`Application Type:
`
`Utility under 35 USC 111 (a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`yes
`
`CARD
`
`$2080
`
`RAM confirmation Number
`
`0329171NTEFSW15025400
`
`Deposit Account
`
`Authorized User
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 013
`
`

`

`File Listing:
`
`Document
`Number
`
`Document Description
`
`File Name
`
`1
`
`Application Data Sheet
`
`REGN-008CIPCON2_2017-03-2t
`_ADS.pdf
`
`File Size(Bytes}/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(if appl.)
`
`1823602
`
`2834e41 e919369Sad5d6080d920b4006ce
`dce46c
`
`no
`
`9
`
`Warnings:
`
`Information:
`
`2
`
`Warnings:
`
`Information:
`
`529155
`
`REG N-008CI PCON2_S pecificati
`on.pdf
`
`66488c5 3 63 7f4 b771 5 ffe 32f0 b65 96663f6e(
`2cd
`
`yes
`
`24
`
`Multipart Description/PDF files in .zip description
`
`Document Description
`
`Start
`
`End
`
`Specification
`
`Claims
`
`Abstract
`
`21
`
`23
`
`24
`
`1
`
`22
`
`24
`
`105393
`
`3
`
`Drawings-only black and white line
`drawings
`
`REGN-008CIPCON2_Figure.pdf
`
`no
`
`1
`
`2d582f64Sd0c5d 17d717e589b029a39331 ~
`91bdb
`
`Warnings:
`
`The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the
`Image File Wrapper and may affect subsequent processing
`
`Information:
`
`4
`
`Oath or Declaration filed
`
`REGN-008CIPCON2_declaration
`.pdf
`
`173097
`
`6bda7272374e6af80c8c3d8cf30d012e465
`b588
`
`no
`
`2
`
`Warnings:
`
`The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the
`Image File Wrapper and may affect subsequent processing
`
`Information:
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 014
`
`

`

`5
`
`65192
`
`REGN-008CIPCON2_2017-03-2t
`_pre_amend_asfld.pdf
`
`da 1 c454ceb9521 e936f1 b0bea05fe671224
`82d93
`
`yes
`
`8
`
`Multipart Description/PDF files in .zip description
`
`Document Description
`
`Start
`
`End
`
`Preliminary Amendment
`
`Specification
`
`Claims
`
`Applicant Arguments/Remarks Made in an Amendment
`
`Warnings:
`
`Information:
`
`1
`
`2
`
`6
`
`8
`
`1
`
`2
`
`3
`
`7
`
`27159
`
`6
`
`Sequence Listing
`
`REGN-0008CIPCON2_seq_list_t
`rans.pdf
`
`15712f98903ec6052e 7e5f716b4a6b70169
`01474
`
`no
`
`1
`
`Warnings:
`
`Information:
`
`7
`
`Sequence Listing (Text File)
`
`REGN-008CIPCON2_Seqlist.txt
`
`no
`
`-
`
`6076
`
`Warnings:
`
`Information:
`
`8
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`no
`
`2
`
`66a646fa2e7f56edc76cb7306d608b0aede
`4f7b0
`
`37141
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes)
`
`2766815
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 015
`
`

`

`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT /DO/E0/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 181 O), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/R0/1 OS) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 016
`
`

`

`PTO/AIN14 (11-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON2
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2:
`D Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`11
`Inventor
`Legal Name
`
`Prefix Given Name
`
`I El l3eroge
`
`Residence Information (Select One)
`• US Residency
`I State/Province
`City
`frorktown Heights
`
`I t'JY
`
`Middle Name
`p.
`
`I Remove
`
`I
`
`Family Name
`
`fl'ANCOPOULOS
`Non US Residency
`Active US Military Service
`I Country of ResidencJ
`I f.Js
`
`Suffix
`
`I El
`
`Mailing Address of Inventor:
`
`Address 1
`
`~o Regeneron Pharmaceuticals, Inc.
`
`lf77 Old Saw Mill River Road
`
`Address 2
`I lfarrytown
`City
`Postal Code
`
`I State/Province
`I 11as91
`11us
`I Countryi
`All Inventors Must Be Listed - Additional Inventor Information blocks may be
`generated within this form by selecting the Add button.
`
`I ~y
`
`I Add
`
`I
`
`Correspondence Information:
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`36387
`
`Email Address
`
`docket@bozpal.com
`
`Application Information:
`
`I Add Email I
`
`I
`
`I Remove Email I
`
`Title of the Invention
`
`Attorney Docket Number REGN-008CIPCON2
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`I Small Entity Status Claimed D
`
`Application Type
`
`Non provisional
`
`Subject Matter
`
`Utility
`
`Total Number of Drawing Sheets (if any)
`
`1
`11
`
`I Suggested Figure for Publication (if any) 111
`
`T
`
`T
`
`EFSWeb2.2.12
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 017
`
`

`

`PTO/AIN14 (11-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON2
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Filing By Reference:
`Only complete this section when filing an application by reference under 35 U.S.C. 111 (c) and 37 CFR 1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`Application number of the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country
`
`i-
`
`I
`
`Publication Information:
`D Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`Request Not to Publish. I hereby request that the attached application not be published under
`D 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`Please Select One:
`
`• Customer Number
`
`I
`
`US Patent Practitioner IO Limited Recognition (37 CFR 11.9)
`
`Customer Number
`
`~6387
`
`Domestic Benefit/National Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate
`National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes
`the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the "Application Number" field blank.
`I·
`
`I Remove I
`
`Prior Application Status
`
`!='ending
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`I
`
`j:ontinuation of
`
`I· 14972560
`
`~015-12-17
`
`EFS Web 2.2.12
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 018
`
`

`

`PTO/AIN14 (11-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON2
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Prior Application Status
`
`!='atenled
`
`Application
`Number
`
`Continuity Type
`
`114972560
`
`ponlinuation of
`
`Prior Application Status
`
`t=xpired
`
`.
`
`Prior Application
`Number
`I· 113940370
`
`.
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`~3940370
`
`Continuation in part of
`
`Prior Application Status ~xpired
`
`. PCT /US2012/020855
`.
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`tcT /US2012/020855
`
`Claims benefit of provisional
`
`Prior Application Status ~xpired
`
`. 61432245
`.
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`tcT /US2012/020855
`
`Claims benefit of provisional
`
`Prior Application Status Expired
`
`. 61434836
`.
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`tcT /US2012/020855
`
`J:laims benefit of provisional
`
`. 61561957
`
`Filing Dale
`(YYYY-MM-DD)
`
`I Remove I
`Issue Dale
`(YYYY-MM-DD)
`
`Patent Number
`
`~013-07-12
`
`p254338
`
`~016-02-09
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`~012-01-11
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`~011-01-13
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`~011-01-21
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`~011-11-21
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`I Add
`
`I
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDXi the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the POX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the lime period specified in 37 CFR 1.55(g)(1 ).
`
`Application Number
`
`Filing Date (YYYY-MM-DD)
`I
`I
`I
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`Countryi
`
`I Remove I
`Access Codei (if applicable)
`
`I Add
`
`I
`
`EFS Web 2.2.12
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 019
`
`

`

`PTO/AIN14 (11-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number REGN-008CIPCON2
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`D 16,2013_
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`EFS Web 2.2.12
`
`APOTEX V. REGENERON IPR2022-01524
`REGENERON EXHIBIT 2007 PAGE 020
`
`

`

`PTO/AIN14 (11-15)
`Approved for use through 04/30/2017. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`REGN-008CIPCON2
`
`Application Number
`
`Title of Invention
`
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written
`authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see
`paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant
`application (see paragraph Bin subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A or B or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an
`application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind
`authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Priority Document Exchange (PDXl - Unless box A in subsection 2 (opt-out of authorization) is checked, the
`undersigned hereby grants the USPTO authority to provide the European Paten